AXR-270 is a pharmacologically differentiated novel steroid (selective glucocorticoid receptor agonist, SeGRA) that has broad potential for treatment of ocular inflammation and is being developed using a proprietary formulation for once daily administration to the eyelid. AXR-270 has been tested extensively in preclinical models of efficacy and safety and has achieved clinical proof-of-concept in patients with DED.
AXR-270